IDWeek 2021: Clinical Impact of New Data*

Data from 1998-2018 suggest interventions are needed to reduce disparities in mortality among women and Black people.

Data showed increases in BMI in all groups but no marked differences between regimens at Week 144 for treatment-emergent diabetes or hypertension or for changes in BMI.

Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.

In real-world cohort, early weight gain following ART initiation associated with excessive weight gain at 2 years.

Limited treatment-emergent lenacapavir resistance occurred after 28 weeks of oral or subcutaneous lenacapavir plus FTC/TAF.

Analysis of international registry data through January 2021 shows that prevalence of birth defects with prenatal DTG is comparable with that seen in the general population.

Pilot study results support feasibility as first-line therapy in a test-and-treat setting, including in patients with a high HIV-1 RNA at baseline (ie, >500,000 copies/mL).

In a web-based survey, US participants who reported being informed of the U=U campaign had more favorable health outcomes regarding self-reported viral suppression, optimal sexual and mental health, and treatment satisfaction vs those not informed of U=U.

Despite increasing PrEP uptake in people at high-risk of HIV acquisition in the United States, overall use remains low, especially in populations such as those insured by Medicaid, young adults, and women.

Switching to DTG/3TC continues to show high levels of virologic suppression, favorable safety and tolerability, and a high barrier to resistance through 3 years.